Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.
about
Emerging options for the management of non-small cell lung cancer.Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
P2860
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Erlotinib in patients with adv ...... and a novel surrogate marker.
@ast
Erlotinib in patients with adv ...... and a novel surrogate marker.
@en
type
label
Erlotinib in patients with adv ...... and a novel surrogate marker.
@ast
Erlotinib in patients with adv ...... and a novel surrogate marker.
@en
prefLabel
Erlotinib in patients with adv ...... and a novel surrogate marker.
@ast
Erlotinib in patients with adv ...... and a novel surrogate marker.
@en
P2093
P2860
P1433
P1476
Erlotinib in patients with adv ...... and a novel surrogate marker.
@en
P2093
Bettina Temmesfeld-Wollbrück
Daniel Binder
Norbert Suttorp
Peter Schlattmann
Ralf-Harto Hübner
Thomas Beinert
P2860
P2888
P304
P356
10.1007/S12032-010-9767-X
P577
2010-12-14T00:00:00Z
P6179
1046115676